Michal-Kamil Chodyla1, Matthias Eiber2, Axel Wetter1, Isabel Rauscher3. 1. Klinik für Radiologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Deutschland. 2. Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland. 3. Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland. isabel.rauscher@tum.de.
Abstract
BACKGROUND: Recently, the use of prostate-specific membrane antigen (PSMA) tracers like 68Ga-PSMA-11 in positron emission tomography (PET) have shown promising results and are helping to improve care for patients with prostate cancer (PC). PURPOSE: In the following we review the current literature on PSMA-ligand PET, in particular with regard to the currently increasing replacement of 68Ga-PSMA ligands by 18F-labeled PSMA ligands. RESULTS: PSMA-ligand PET is most frequently used for biochemical recurrence. Here, 68Ga-PSMA-11 PET/CT shows superior detection rates compared to conventional imaging modalities, especially in small, morphologically unsuspicious lesions, even at low PSA values. Furthermore, 68Ga-PSMA PET imaging seems to be an encouraging alternative for staging of high-risk patients, particularly in combination with multiparametric MRI. CONCLUSION: The use of PSMA-ligand PET has revolutionized PC imaging. Thus, PSMA-ligand PET is expected to play an even greater role in PC diagnostics in the future, especially as 18F-labeled PSMA ligands are now increasingly used. However, simultaneous image analysis of PET and CT as well as a differentiated image evaluation (clinical context, knowledge of common pitfalls) is mandatory.
BACKGROUND: Recently, the use of prostate-specific membrane antigen (PSMA) tracers like 68Ga-PSMA-11 in positron emission tomography (PET) have shown promising results and are helping to improve care for patients with prostate cancer (PC). PURPOSE: In the following we review the current literature on PSMA-ligand PET, in particular with regard to the currently increasing replacement of 68Ga-PSMA ligands by 18F-labeled PSMA ligands. RESULTS:PSMA-ligand PET is most frequently used for biochemical recurrence. Here, 68Ga-PSMA-11 PET/CT shows superior detection rates compared to conventional imaging modalities, especially in small, morphologically unsuspicious lesions, even at low PSA values. Furthermore, 68Ga-PSMA PET imaging seems to be an encouraging alternative for staging of high-risk patients, particularly in combination with multiparametric MRI. CONCLUSION: The use of PSMA-ligand PET has revolutionized PC imaging. Thus, PSMA-ligand PET is expected to play an even greater role in PC diagnostics in the future, especially as 18F-labeled PSMA ligands are now increasingly used. However, simultaneous image analysis of PET and CT as well as a differentiated image evaluation (clinical context, knowledge of common pitfalls) is mandatory.
Authors: Isabel Rauscher; Charlotte Düwel; Bernhard Haller; Christoph Rischpler; Matthias M Heck; Jürgen E Gschwend; Markus Schwaiger; Tobias Maurer; Matthias Eiber Journal: Eur Urol Date: 2018-01-19 Impact factor: 20.096
Authors: Laura Evangelista; Fabio Zattoni; Andrea Guttilla; Giorgio Saladini; Filiberto Zattoni; Patrick M Colletti; Domenico Rubello Journal: Clin Nucl Med Date: 2013-05 Impact factor: 7.794
Authors: Urs J Muehlematter; Irene A Burger; Anton S Becker; Khoschy Schawkat; Andreas M Hötker; Cäcilia S Reiner; Julian Müller; Niels J Rupp; Jan H Rüschoff; Daniel Eberli; Olivio F Donati Journal: Radiology Date: 2019-09-10 Impact factor: 11.105
Authors: Lindsey A Torre; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-14 Impact factor: 4.254
Authors: Isabel Rauscher; Markus Krönke; Michael König; Andrei Gafita; Tobias Maurer; Thomas Horn; Kilian Schiller; Wolfgang Weber; Matthias Eiber Journal: J Nucl Med Date: 2019-06-28 Impact factor: 11.082
Authors: Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Cordula A Jilg; Vanessa Drendel; H Christian Rischke; Teresa Beck; Werner Vach; Kathrin Schaal; Ulrich Wetterauer; Wolfgang Schultze-Seemann; Philipp T Meyer Journal: Theranostics Date: 2017-04-10 Impact factor: 11.556